Potency of whole virus particle and split virion vaccines using dissolving microneedle against challenges of H1N1 and H5N1 influenza viruses in mice

Nakatsukasa, Akihiro; Kuruma, Koji; Okamatsu, Masatoshi; Hiono, Takahiro; Suzuki, Marina Satika; Matsuno, Keita; Kida, Hiroshi; Oyamada, Takayoshi; Sakoda, Yoshihiro

doi:10.1016/j.vaccine.2017.04.009

Cited by 20 publications

(10 citation statements)

References 28 publications

(35 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

“…In particular, studies of influenza vaccination that compared MAP injection and a no-treatment group found that the MAP application conferred greater protective immunity. 28,29 Similar observations were documented when comparing MAP injection with subcutaneous injection 30,31 and intranasal administration. 32 Notably, the MAP application induced not only comparable protective efficacy [33][34][35][36][37] but also better protection event [38][39][40][41] compared to intramuscular (IM) administration.…”

Section: Preclinical Studies Of Vaccine Mapsupporting

confidence: 67%

Progress in microneedle array patch (MAP) for vaccine delivery

Nguyen

Kim

et al. 2020

Human Vaccines & Immunotherapeutics

View full text Add to dashboard Cite

A microneedle array patch (MAP) has been developed as a new delivery system for vaccines. Preclinical and clinical trials with a vaccine MAP showed improved stability, safety, and immunological efficacy compared to conventional vaccine administration. Various vaccines can be delivered with a MAP. Currently, microneedle manufacturers can mass-produce pharmaceutical MAP and cosmetic MAP and this mass-production system can be adapted to produce a vaccine MAP. Clinical trials with a vaccine MAP have shown comparable efficacy with conventional administration, and discussions about regulations for a vaccine MAP are underway. However, there are concerns of reasonable cost, mass production, efficacy, and safety standards that meet FDA approval, as well as the need for feedback regarding the best method of administration. Currently, microneedles have been studied for the delivery of many kinds of vaccines, and preclinical and clinical studies of vaccine microneedles are in progress. For the foreseeable future, some vaccines will continue to be administered with syringes and needles while the use of a vaccine MAP continues to be improved because of the advantages of less pain, self-administration, improved stability, convenience, and safety.

show abstract

Section: Preclinical Studies Of Vaccine Mapsupporting

confidence: 67%

Progress in microneedle array patch (MAP) for vaccine delivery

Nguyen

Kim

et al. 2020

Human Vaccines & Immunotherapeutics

View full text Add to dashboard Cite

show abstract

“…The influenza A virus PR8 (H1N1) strain is lethal in mice, who succumb within 8 dpi in the presence of a concentration of 10 MLD 50 [ 17 ]. Influenza onset correlates with inflammatory cytokine expression, and neuroinflammation due to influenza virus infection releases inflammatory cytokines and can cause lung tissue damage [ 30 ].…”

Section: Discussionmentioning

confidence: 99%

“…Virus challenge in mice was conducted as previously described [ 17 ]. After 7 weeks of feeding the mice a standard or 25(OH)D 3 -supplemented diet, PR8 (H1N1) was inoculated intranasally using 10 times the 50% mouse lethal dose (MLD 50 ) in 30 µL per mouse under anesthesia.…”

Section: Methodsmentioning

confidence: 99%

Oral Supplementation of the Vitamin D Metabolite 25(OH)D3 Against Influenza Virus Infection in Mice

et al. 2020

Self Cite

View full text Add to dashboard Cite

Vitamin D is a fat-soluble vitamin that is metabolized by the liver into 25-hydroxyvitamin D [25(OH)D] and then by the kidney into 1,25-dihydroxyvitamin D [1,25(OH)2D], which activates the vitamin D receptor expressed in various cells, including immune cells, for an overall immunostimulatory effect. Here, to investigate whether oral supplementation of 25-hydroxyvitamin D3 [25(OH)D3], a major form of vitamin D metabolite 25(OH)D, has a prophylactic effect on influenza A virus infection, mice were fed a diet containing a high dose of 25(OH)D3 and were challenged with the influenza virus. In the lungs of 25(OH)D3-fed mice, the viral titers were significantly lower than in the lungs of standardly fed mice. Additionally, the proinflammatory cytokines IL-5 and IFN-γ were significantly downregulated after viral infection in 25(OH)D3-fed mice, while anti-inflammatory cytokines were not significantly upregulated. These results indicate that 25(OH)D3 suppresses the production of inflammatory cytokines and reduces virus replication and clinical manifestations of influenza virus infection in a mouse model.

show abstract

“…Cutaneous antigen delivery 12 using variety of devices and vaccines 13 including influenza vaccines 14 – 20 is an active and promising area of research with important implications for public health. We 17 – 19 , 21 – 23 and other investigators 24 – 28 have observed improved immune responses to influenza vaccination by MNPs. Improved response to skin-delivered antigens occurs due to a network of immunoregulatory cells in skin 29 – 31 including specialized sets of resident antigen-presenting cells (APC) 32 .…”

Section: Introductionmentioning

confidence: 58%

Skin immunization by microneedle patch overcomes statin-induced suppression of immune responses to influenza vaccine

Vassilieva

Wang

et al. 2017

Sci Rep

View full text Add to dashboard Cite

Recent studies indicated that in elderly individuals, statin therapy is associated with a reduced response to influenza vaccination. The present study was designed to determine effects on the immune response to influenza vaccination induced by statin administration in a mouse model, and investigate potential approaches to improve the outcome of vaccination on the background of statin therapy. We fed middle aged BALB/c mice a high fat “western” diet (WD) alone or supplemented with atorvastatin (AT) for 14 weeks, and control mice were fed with the regular rodent diet. Mice were immunized with a single dose of subunit A/Brisbane/59/07 (H1N1) vaccine, either systemically or with dissolving microneedle patches (MNPs). We observed that a greater age-dependent decline in the hemagglutinin inhibition titers occurred in systemically-immunized mice than in MNP- immunized mice. AT dampened the antibody response in the animals vaccinated by either route of vaccine delivery. However, the MNP-vaccinated AT-treated animals had ~20 times higher total antibody levels to the influenza vaccine than the systemically vaccinated group one month postvaccination. We propose that microneedle vaccination against influenza provides an approach to ameliorate the immunosuppressive effect of statin therapy observed with systemic immunization.

show abstract

Potency of whole virus particle and split virion vaccines using dissolving microneedle against challenges of H1N1 and H5N1 influenza viruses in mice

Cited by 20 publications

References 28 publications

Progress in microneedle array patch (MAP) for vaccine delivery

Progress in microneedle array patch (MAP) for vaccine delivery

Oral Supplementation of the Vitamin D Metabolite 25(OH)D3 Against Influenza Virus Infection in Mice

Skin immunization by microneedle patch overcomes statin-induced suppression of immune responses to influenza vaccine

Contact Info

Product

Resources

About